Vertex Pharmaceuticals (VRTX) Prepaid Assets (2009 - 2026)
Vertex Pharmaceuticals' (VRTX) quarterly Prepaid Assets came in at $720.8 million in Q1 2026, up 12.13% year-on-year from $642.8 million in Q1 2025, and down 15.53% quarter-over-quarter from $853.3 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Prepaid Assets (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Prepaid Assets history runs 18 years deep, the most recent figure standing at $720.8 million for Q1 2026.
- On a quarterly basis, Prepaid Assets rose 12.13% year-over-year to $720.8 million in Q1 2026; TTM through Mar 2026 was $720.8 million, a 12.13% increase from a year earlier, with the FY2025 full-year figure at $853.3 million, up 28.18% from the prior year.
- Prepaid Assets fell to $720.8 million in Q1 2026 per VRTX's latest filing, from $853.3 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $853.3 million in Q4 2025 and bottomed at $84.3 million in Q4 2023.
- The 5-year median for Prepaid Assets is $553.5 million (2022), against an average of $568.9 million.
- Across the five-year window, Prepaid Assets slumped 84.77% in 2023 and soared 689.68% in 2024, its largest moves.
- Year by year, Prepaid Assets stood at $553.5 million in 2022, then slumped by 84.77% to $84.3 million in 2023, then surged by 689.68% to $665.7 million in 2024, then rose by 28.18% to $853.3 million in 2025, then slipped by 15.53% to $720.8 million in 2026.
- Per Business Quant, the three latest VRTX Prepaid Assets figures stand at $720.8 million (Q1 2026), $853.3 million (Q4 2025), and $709.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 720.80 Mn |
| Dec 31, 2025 | 853.30 Mn |
| Sep 30, 2025 | 709.40 Mn |
| Jun 30, 2025 | 652.30 Mn |
| Mar 31, 2025 | 642.80 Mn |
| Dec 31, 2024 | 665.70 Mn |
| Sep 30, 2024 | 449.20 Mn |
| Jun 30, 2024 | 575.40 Mn |
| Mar 31, 2024 | 511.10 Mn |
| Dec 31, 2023 | 84.30 Mn |
| Sep 30, 2023 | 540.20 Mn |
| Jun 30, 2023 | 476.90 Mn |
| Mar 31, 2023 | 468.70 Mn |
| Dec 31, 2022 | 553.50 Mn |
| Sep 30, 2022 | 726.90 Mn |
| Jun 30, 2022 | 549.50 Mn |
| Mar 31, 2022 | 491.50 Mn |
| Dec 31, 2021 | 545.80 Mn |
| Sep 30, 2021 | 457.83 Mn |
| Jun 30, 2021 | 498.76 Mn |